 Times LIVE | Pfizer drug fails in Phase III NHL trial PharmaTimes In the trial, inotuzumab ozogamicin was administered once-a-month schedule in combination with Roche's Rituxan (rituximab) and compared with either Teva's Treanda (bendamustine) plus rituximab or Eli Lilly's Gemzar (gemcitabine) plus rituximab). Pfizer discontinues phase III study of inotuzumab ozogamicin in relapsed or ... Correction: Pfizer-Study Halted story Non-Hodgkin Rx Trial Halted |
